Cite
MLA Citation
A. Bardia et al.. “P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator's choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy.” Breast, vol. 68, 2023, pp. S23–. http://access.bl.uk/ark:/81055/vdc_100180203875.0x000024